Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma-Reference-Cited by-同舟云学术

Allogeneic Blood or Marrow Transplantation with Nonmyeloablative Conditioning and High-Dose Cyclophosphamide-Based Graft-versus-Host Disease Prophylaxis for Secondary Central Nervous System Lymphoma

Published:2021-10 Issue:10 Volume:27 Page:863.e1-863.e5
ISSN:2666-6367
Container-title:Transplantation and Cellular Therapy
language:en
Short-container-title:Transplantation and Cellular Therapy

Author:

Sterling Cole H.,Tsai Hua-Ling,Holdhoff Matthias,Bolaños-Meade Javier,Luznik Leo,Fuchs Ephraim J.,Huff Carol Ann,Gocke Christian B.,Ali Syed Abbas,Borrello Ivan M.,Varadhan Ravi,Jones Richard J.,Gladstone Douglas E.,Ambinder Richard F.,Wagner-Johnston Nina,Swinnen Lode J.,Imus Philip H.

Publisher

Elsevier BV

Subject

Transplantation,Cell Biology,Hematology,Molecular Medicine,Immunology and Allergy

Reference37 articles.

1. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model;Hollender;Ann Oncol,2002

2. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab;Feugier;Ann Oncol,2004

3. CNS International Prognostic Index: a risk model for CNS relapse in patients with diffuse large B-cell lymphoma treated with R-CHOP;Schmitz;J Clin Oncol,2016

4. Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment;van Besien;Leuk Lymphoma,2008

5. High-dose therapy with hematopoietic cell transplantation for patients with central nervous system involvement by non-Hodgkin's lymphoma;Alvarnas;Biol Blood Marrow Transplant,2000

Cited by 5 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Nivolumab for CNS relapsed refractory primary mediastinal B-cell lymphoma: case report and review of the literature;Leukemia & Lymphoma;2024-09-03

2. How I treat secondary CNS involvement by aggressive lymphomas;Blood;2023-11-23

3. Outcomes of allogeneic hematopoietic stem cell transplantation in secondary central nervous system lymphoma: a case series;Leukemia & Lymphoma;2023-01-17

4. Performance status, comorbidities, and cycles of methotrexate exert the greatest influence on outcomes of primary and secondary CNS lymphomas: the Lexington experience;Annals of Hematology;2022-11-11

5. SOHO State of the Art Updates and Next Questions: Prophylaxis and Management of Secondary CNS Lymphoma;Clinical Lymphoma Myeloma and Leukemia;2022-10